download PDF - Newron

More documents

Recommendations

Info

Corporate Profile Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Phase III trials of safinamide for the treatment of Parkinson’s disease (PD) have recently been completed and Newron anticipates a potential filing in the EU and US, in 2013. Zambon Group has the rights to commercialize safinamide globally, excluding Japan and other key Asian territories, and Meiji Seika has the rights to develop and commercialize safinamide in Japan and other key Asian territories. Newron’s additional projects are at various stages of preclinical and clinical development, including HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases. www.newron.com
Key Corporate Events Completion of the phase III development programme for safinamide as an add-on therapy for Parkinson’s disease Agreement signed with Zambon for strategic collaboration and licence to safinamide covering global rights excluding Japan and key Asian territories Agreement signed with Meiji Seika for licence to safinamide in Japan and key Asian territories New data on safinamide presented as late-breaking news at AAN 2011 Annual Meeting Approval of IND by the US FDA for NW-3509, a novel compound with potential as an add-on treatment for patients with schizophrenia FDA approval of ralfinamide trial in non-responding patients with severe neuropathic pain of specific causes Global rights to safinamide regained from Merck Serono Agreement signed with Merck KGaA to develop two compounds for CNS diseases
Page 1: Annual Report 2011
Page 6 and 7: Shareholders’ Letter Rolf Stahel
Page 8 and 9: Drug Portfolio Safinamide Adjunctiv
Page 10 and 11: Information for Investors Stock exc
Page 13 and 14: Corporate Governance
Page 15 and 16: Group Structure and Shareholders Ne
Page 17 and 18: To the best of Newron’s knowledge
Page 19 and 20: ight by the Company’s current sha
Page 21 and 22: Stock-based remuneration (stock opt
Page 23 and 24: Rolf Stahel has been the Chairman o
Page 25 and 26: Responsibilities and organization P
Page 27 and 28: Subcommittees The Board has formed
Page 29 and 30: Senior Management Members of the se
Page 31 and 32: Compensation, Shareholdings and Loa
Page 33 and 34: The total gross compensation and th
Page 35 and 36: Attendance and voting rights To att
Page 37 and 38: Auditors Upon proposal by the manag
Page 39: Information Policy Newron undertake
Page 42 and 43: Consolidated Statement of Income (I
Page 44 and 45: Consolidated Statement of Changes i
Page 46 and 47: Notes to the Consolidated Financial
Page 48 and 49: The following new standards, amendm
Page 50 and 51: (‘the functional currency’). Th
Page 52 and 53:
P Share capital Ordinary shares and
Page 54 and 55:
The Group did not enter into foreig
Page 56 and 57:
sell of the property, plant and equ
Page 58 and 59:
Other expenses increased by EUR 1,4
Page 60 and 61:
14 Intangible assets (In thousand e
Page 62 and 63:
Government grants receivable includ
Page 64 and 65:
A summary of the granted options is
Page 66 and 67:
Amounts recognized under staff cost
Page 68 and 69:
29 Financial instruments by categor
Page 70 and 71:
Auditors’ Report 68 Newron Annual
Page 72 and 73:
Glossary Activities of Daily Living
Page 74 and 75:
In vitro A biological or chemical p
Page 76 and 77:
Product Candidate (or Clinical Comp
Page 78:
Imprint Publisher Newron Pharmaceut
show all

download PDF - Newron

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?